ArticleCancer management and research2025
The Efficacy and Safety of Anlotinib Treatment for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Who Achieved Stable Disease (SD) After Two Cycles of First-Line Chemotherapy Combined with Immunotherapy: A Retrospective Cohort Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The maintenance treatment with anlotinib can improve the efficacy in advanced non-small cell lung cancer (NSCLC) patients, but the appropriate patient population are still undefined. This study aimed to evaluate the efficacy and safety of adding anlotinib treatment in advanced NSCLC patients who achieved disease stabilization after two cycles of first-line chemotherapy combined with immunotherapy (CIO). Materials and Methods: We retrospectively reviewed clinical data of patients with advanced NSCLC who received anlotinib treatment after achieving stable disease (SD) following two cycles of first-line CIO in our hospital. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints included objective response rate (ORR), disease control rate (DCR), and Adverse Events (AEs). Results: A total of 38 patients were included in this study. The median age was 65 years (range, 47-77), with 73.68% male and 26.32% female. The median PFS and OS were 6.5 months and 12.0 months, respectively. The ORR and DCR were 34.21% and 68.42%, respectively. Subgroup analysis results showed that patients who experienced hypertension, proteinuria, and hand-foot syndrome during treatment had better efficacy. Mechanistic analysis further suggested that this regimen may enhance the anti-tumor immunity by depleting Tregs, thereby exerting a synergistic effect. Importantly, the overall AEs of this regimen were manageable, supporting the suitability of this treatment modality. Conclusion: Adaptive use of Anlotinib could be a safe and effective option in advanced NSCLC patients who achieved SD after two cycles of first-line CIO. This regimen is expected to become an important option for precision and personalized treatment of NSCLC. However, due to the limitations of retrospective nature, its clinical value needs to be further confirmed by prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.